Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Presentation THT Abstracts 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presenter: Alexandra Steverson

March 05, 2024

Presentation ARCH 2022

First Things First – Pharmacotherapy for HFrEF

Presenter: Georges Chahoud

April 23, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

Presentation AHA 2016

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Presenter: Dirk J. van Veldhuisen

November 16, 2016

Advertisement

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

First Things First – Pharmacotherapy for HFrEF

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content